Market Place
Sourcing Support
Biocon Biologics looks to trim $300 million debt in 1 year
19 Nov 2024 //
ECONOMICTIMES
Will launch 3 biosimilars globally in 2-3 years: Biocon Biologics
05 Nov 2024 //
BUSINESS STD
Biocon Biologics` Bengaluru Unit Receives Voluntary FDA Action
30 Oct 2024 //
ECONOMICTIMES
Biocon refinances $ 1.1 bn long-term debt through USD bonds
04 Oct 2024 //
EXPRESSPHARMA
USFDA Completes Inspection At Biocon Biologics’ Insulin Facility
30 Sep 2024 //
INDPHARMAPOST
Biocon signs agreement with Tabuk Pharma for GLP-1 products
27 Sep 2024 //
EXPRESSPHARMA
Biocon Global to raise funds through senior secured notes
26 Sep 2024 //
INDPHARMAPOST
Biocon Biologics to Present Dermatology Data at EADV Congress 2024
25 Sep 2024 //
PR NEWSWIRE
FDA Issues Form 483 to Biocon Biologics Limited
06 Sep 2024 //
FDA
EMA approves Biocon Biologics’ new mAbs facility in India
24 Jun 2024 //
INDIANPHARMAPOST
Biocon Gets US Approval For Biosimilar Aflibercept Yesafili
21 May 2024 //
PR NEWSWIRE
USFDA approves Biocon Biologics` biosimilar product to treat ophthalmology
21 May 2024 //
ECONOMICTIMES
Biocon Biologics’ receives FDA approval for Biosimilar Aflibercept for Yesafili
21 May 2024 //
INDINPHARMAPOST
US FDA approves two biosimilars for blockbuster eye drug Eylea
21 May 2024 //
REUTERS
Biocon Biologics’ Yesafili (aflibercept-jbvf) Receives Approval In U.S
20 May 2024 //
FDA
Biocon Biologics gears up to challenge Stelara in the US
29 Feb 2024 //
FIERCE PHARMA
Biocon Biologics focusing on market share gains of biosimilars in key markets
13 Feb 2024 //
ECONOMIC TIMES
Biocon Concludes Integration of Biosimilars Business in 120 countries
18 Dec 2023 //
PR NEWSWIRE
Biocon Biologics recognized as an Asia IP Elite for 2023
17 Dec 2023 //
INDIAN PHARMA POST
Biocon Biologics Completes Integration of Viatris™ Biosimilar Business
30 Nov 2023 //
GLOBENEWSWIRE
Biocon Biologics receives MHRA Approval for Biosimilar Aflibercept ‘Yesafili’
14 Nov 2023 //
INDIAN PHARMA POST
Biocon Biologics announces divestment of two non-core branded formulations
09 Nov 2023 //
INDIAN PHARMA POST
Biocon Biologics names Kedar Upadhye as new CFO
19 Oct 2023 //
ECONOMIC TIMES
Biocon`s Malaysia insulin facility classified by FDA for official action
18 Oct 2023 //
ECONOMIC TIMES
On track to integrate major part Viatris``acquired biosimilars biz this fiscal
30 Aug 2023 //
ECONOMICTIMES
Biocon facility in Malaysia found to have issues once again by the FDA
15 Aug 2023 //
ENDPTS
Biocon Biologics to integrate Viatris` US biosimilar business by Q2 end`
14 Aug 2023 //
ECONOMIC TIMES
Competition Commission of India clears Kotak-Biocon Biologics deal
11 Aug 2023 //
ECONOMIC TIMES
Biocon Biologics announces top leadership appointments
04 Aug 2023 //
ECONOMIC TIMES
